Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PINNACLE: Poziotinib vs Docetaxel in NSCLC with HER2 Exon 20 Mutations
NCT05378763Phase 3Suspended
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- May 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of poziotinib in non-small cell lung cancer (NSCLC), sponsored by Spectrum Pharmaceuticals, Inc.. Started May 2022; status: suspended.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05378763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378763.